| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-06-30 | Scil Proteins (Germany) Anabasis Pharma (Italy) | manufacturing process for recombinant human Nerve Growth Factor (rhNGF) | Eye diseases including neurotrophic keratitis, dry eye and glaucoma | licensing |
Ophtalmological diseases | Production agreement |
| 2011-06-29 | AstraZeneca (UK) PTC Therapeutics (USA - NJ) | PTC's proprietary GEMS™ technology (Gene Expression Modulation by Small-molecules) | cancer and other diseases for which there is a great unmet medical need | research - R&D - licensing | Cancer - Oncology | R&D agreement |
| 2011-06-29 | Cellectis (France) Pregenen (USA) | genome engineering tools | research - R&D | R&D agreement | ||
| 2011-06-29 | Exonhit (France) Almac Diagnostics (UK) | AclarusDx® (blood-based test intended to help in the diagnosis of Alzheimer’s disease) | Alzheimer's disease | Services |
Neurodegenerative diseases | Services contract |
| 2011-06-29 | Sanofi (France) Weill CornellMedical College (USA) | tuberculosis | research - R&D | Infectious diseases | R&D agreement | |
| 2011-06-29 | UCB (Belgium) Harvard University (USA) | research - R&D | CNS diseases - Immunology | R&D agreement | ||
| 2011-06-28 | Argenta (UK - Galapagos's subsidiary) Pulmagen Therapeutics (UK) | chemistry, biology, ADMET/PK and pharmacology services | Services |
Respiratory diseases | Services contract | |
| 2011-06-27 | Evotec (Germany) Ono Pharmaceutical (Japan) | small molecules targeting an ion channel implicated in cardiovascular, CNS and urological diseases | research - R&D | Cardiovascular diseases - CNS diseases - Urological diseases | R&D agreement | |
| 2011-06-27 | Flamel Technologies (France) Digna Biotech (Spain) | preclinical and clinical products including twoTransforming Growth Factor beta-1 (TGF-beta1) inhibitor (P144 and P17) and Methylthiadenosine | development |
Cancer - Oncology - Inflammatory diseases - Autoimmune diseases - Ophtalmological diseases | Development agreement | |
| 2011-06-27 | BiolineRx (Israel) Yissum Research Development Company (Israel) | BL-7040 | inflammatory bowel disease | development |
Inflammatory diseases | Development agreement |
| 2011-06-24 | Evotec (Germany) Roche (Switzerland) | protein-activity based biomarkers using PhosphoScout® platform | research - R&D - collaboration | Cancer - Oncology | R&D agreement | |
| 2011-06-24 | Immune Pharmaceuticals (Israel) iCo Therapeutics (Canada) | bertilimumab (iCo-008) | licensing |
Inflammatory diseases - Immunological diseases | Licensing agreement | |
| 2011-06-23 | Medivir (Sweden) Daewoong Pharmaceutical (South Korea) | Xerclear® (Xerese® in the USA) combination of 5% acyclovir and 1% hydrocortisone in Medivir’s proprietary cream formulation | recurrent herpes labialis | distribution |
Infectious diseases | Distribution agreement |
| 2011-06-22 | Apeiron Biologics (Austria) - Children’s Cancer Research Institute (CCRI) - European Neuroblastoma Research Network (SIOPEN) | antibody ch14.18 | neuroblastoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2011-06-21 | Abbott (USA) Biotest (Germany) | BT-061 | rheumatoid arthritis -psoriasis | development |
Autoimmune diseases – Dermatological diseases - Inflammatory diseases - Rheumatic diseases | Development agreement |
| 2011-06-21 | Vivalis (France) Kyoto Biken Laboratories (Japan) | EB66® duck embryonic stem cell line | licensing |
Veterinary medicine | Licensing agreement | |
| 2011-06-20 | Pluristem Therapeutics (Israel) United Therapeutics (USA) | PLacental eXpanded (PLX) cells | pulmonary arterial hypertension | licensing |
Rare diseases - Cardiovascular diseases - Lung diseases | Licensing agreement |
| 2011-06-17 | Algenics (France) Novimmune (Switzerland) | production of two monoclonal therapeutic antibodies | R&D |
R&D agreement | ||
| 2011-06-16 | Reneuron(UK)Schepens Eye Research Institute (USA) | ReN003 stem cell therapy programme | diseases of retina | Patent and licensing |
Ophtalmological diseases | Licensing agreement |
| 2011-06-16 | Sanofi (France) Audion Therapeutics (The Netherlands) | optimization of small molecules by using a regenerative medicine approach | hearing loss | R&D |
Otorhinolaryngology | R&D agreement |
